Karyopharm to Participate in Baird's Biotech Discovery Series

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) announced that its senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET.

Dr. Harrison is Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and is described as a leading international expert in myelofibrosis. A live webcast will be available under the company's Investor "Events & Presentations" page and will be posted for replay after the event.

Key Figures

Event date December 10, 2025 Date of Baird Biotech Discovery Series virtual fireside chat

Event time 12:00 p.m. ET Scheduled start time for the virtual fireside chat

Market Reality Check

$5.75 Last Close

Volume Volume 64,486 versus 20-day average 116,803 (relative volume 0.55x) suggests subdued trading ahead of this event update. low

Technical Shares at $5.75 are trading above the 200-day MA of $5.52, but remain 53.82% below the 52-week high of $12.45.

Peers on Argus 1 Up

Within Biotechnology peers, moves are mixed: CUE -3.72%, APLT -5.83%, CAMP -5.8%, PYPD +1.53%, MAIA 0%. Momentum scanner shows only ALXO with notable upside at +7.75% without news, indicating no broad coordinated move around this conference participation headline.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Inducement grants	Neutral	-6.8%	Inducement stock options and RSUs granted to new hires under 2022 plan.
Dec 01	Conference participation	Neutral	+2.3%	Management fireside chat at Piper Sandler healthcare conference with webcast replay.
Nov 03	Inducement RSU grant	Neutral	+4.7%	Single-employee RSU inducement grant under Nasdaq Listing Rule 5635(c)(4).
Nov 03	Earnings and pipeline	Neutral	+4.7%	Q3 2025 results and progress, including SENTRY Phase 3 myelofibrosis enrollment.
Oct 27	Earnings date notice	Neutral	+1.3%	Announcement of Q3 2025 results date and related conference call details.

Recent Company History

Over the last few months, Karyopharm has reported Q3 2025 results with $44.0M revenue and highlighted completion of enrollment in the Phase 3 SENTRY myelofibrosis trial. The company also issued multiple inducement RSU and option grants and participated in investor conferences, with share-price reactions ranging from about -6.78% to +4.66%. Today’s Baird Biotech Discovery Series fireside chat fits into this pattern of ongoing investor-relations outreach rather than a discrete clinical or financial catalyst.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-03

An effective S-3 resale registration dated Nov 3, 2025 covers up to 2,805,688 shares of common stock held or issuable to selling stockholders. The company is not selling any securities and will not receive proceeds from these resales, although it would receive cash if warrants are exercised at the stated exercise price. As of Oct 30, 2025, 17,050,876 shares were outstanding.

Market Pulse Summary

This announcement highlights Karyopharm’s participation in Baird’s Biotech Discovery Series, featuring a virtual fireside chat focused on myelofibrosis and related myeloproliferative neoplasms. It continues a pattern of conference visibility and investor communication rather than introducing new clinical or financial data. In light of prior disclosures around a $33.1M Q3 2025 net loss and going‑concern risks, investors may watch for how management frames trial progress, financing flexibility, and previously registered resales of up to 2,805,688 shares.

Key Terms

myeloproliferative neoplasms medical

"Dr. Harrison is Professor of Myeloproliferative Neoplasms, Clinical Director..."

Myeloproliferative neoplasms are a group of blood cancers caused by the bone marrow producing too many of one or more types of blood cells, which can crowd out normal cells and impair blood flow. Investors pay attention because these conditions create clear medical needs and predictable markets for diagnostics, therapies and follow-up care—similar to a failing factory that creates demand for repair services and replacement parts—affecting drug development, regulatory milestones and potential sales.

myelofibrosis medical

"...and a leading international expert in myelofibrosis."

A bone marrow disorder in which healthy, spongy marrow is gradually replaced by scar tissue, like a garden soil turned to concrete so seeds can’t grow. That replacement reduces production of red and white blood cells and platelets, causing anemia, fatigue, infections and an enlarged spleen. Investors care because the condition creates demand for therapies, clinical trials and regulatory decisions that can materially affect drug sales and company valuations.

AI-generated analysis. Not financial advice.

NEWTON, Mass., Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET. Dr. Harrison is Professor of Myeloproliferative Neoplasms, Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and a leading international expert in myelofibrosis.

A live webcast of the event can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-in-bairds-biotech-discovery-series-302634110.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) present at Baird's Biotech Discovery Series?

Karyopharm will present on Wednesday, December 10, 2025 at 12:00 p.m. ET.

Who from Karyopharm will participate in the December 10, 2025 fireside chat (KPTI)?

The company's senior management team and Dr. Claire Harrison will participate in the virtual fireside chat.

How can investors watch the Karyopharm (KPTI) webcast on December 10, 2025?

Watch the live webcast via the Investor "Events & Presentations" page at https://investors.karyopharm.com/events-presentations.

Will the Karyopharm (KPTI) fireside chat be available after the live event?

Yes. The webcast will be available for replay following the event on the same investor events page.

What is Dr. Claire Harrison’s role mentioned for the Karyopharm (KPTI) presentation?

Dr. Harrison is listed as Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and a leading expert in myelofibrosis.